ReviewRespirology (Carlton, Vic.)2023
Thoracic manifestations of IgG4-related disease.
Review in Respirology (Carlton, Vic.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- Isolated pulmonary IgG4-related disease mimicking infection and malignancy: clinical features and a proposed diagnostic approach.Clinical rheumatology · 2026Article
- Abdominal manifestations of multisystem diseases: a pattern-based imaging review.Abdominal radiology (New York) · 2026Review
- Clinical significance of serum IgE levels in IgG4-related ophthalmic disease: a single-centre study.Eye (London, England) · 2026Article
- MPT64 antigen-induced immune responses as a novel diagnostic tool for tuberculosis.Microbiology spectrum · 2026Article
- Isolated Mediastinal and Hilar Lymphadenopathy as a Manifestation of IgG4-Related Disease Diagnosed by EBUS-Guided Transbronchial Mediastinal Cryobiopsy.Respirology case reports · 2026Article
- Tocilizumab in the treatment of IgG4-related disease involving the carotid artery-case report and literature review.Frontiers in immunology · 2026Review
- Beyond the Th2 paradigm: CD4+ cytotoxic T lymphocytes as key drivers of tissue damage and fibrosis in IgG4-related disease.Frontiers in immunology · 2026Review
- Acute mediastinitis, mediastinal granuloma, and fibrosing mediastinitis: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Case Report: IgG4-related lung disease.Frontiers in immunology · 2026Article
- Isolated IgG4-related lung disease: a case report.AME case reports · 2026Article
- Article
- Clinical characteristics of IgG4-related lung disease: a single-center based experience.Clinical rheumatology · 2025Article
- Clinicopathological Pearls and Diagnostic Pitfalls in IgG4-Related Disease: Challenging Case Series and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- IgG4-related lung disease with pulmonary lesions and recurrent pleural effusion: A case of report.Radiology case reports · 2025Article
- IgG4-related lung disease mimicking COPD: case report and review.BMC pulmonary medicine · 2025Review
- Global research trends and emerging focus areas in IgG4-related disease: a bibliometric and visual analysis.Hereditas · 2025Article
- A Case in Which the Endoscopic Denker's Approach Was Useful in the Diagnosis of IgG4-Related Ophthalmic Disease.Cureus · 2025Article
- When herpes masks a greater threat: A case report of granulomatosis with polyangiitis.Medicine · 2025Article
- Article
- Relapsing polychondritis: tracheobronchial involvement and differential diagnoses.Journal of thoracic disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin G4-related disease (IgG4-RD) is a recently described rare systemic fibroinflammatory disease with an estimated incidence of less than 1 in 100,000 persons per year. The disease can affect virtually any organ and is characterized by unifying histopathological findings. Recently, four subgroups of patients have been characterized: hepatobiliary, head and neck, Mikulicz syndrome and retroperitoneal fibrosis, who illustrate the mainly abdominal and ENT tropism of the disease. Yet, thoracic involvement is not uncommon. It can be detected in up to 30% of patients with systemic IgG4-RD and is the exclusive manifestation of the disease in about 10% of cases. Clinical symptoms are nonspecific and may include dyspnoea, cough or chest pain. Chest CT findings are heterogeneous and primarily include peribronchovascular thickening, nodules, ground-glass opacities and lymphadenopathy. There is no specific diagnostic test for IgG4-RD thoracic involvement, which may mimic malignancy or vasculitis. Therefore, a cautious approach is needed to make an accurate diagnosis: a search for extra-thoracic manifestations, elevated serum IgG4 levels, circulating levels of plasmablasts and pathologic evidence of disease is warranted. Although very suggestive, neither the presence of a polyclonal IgG4 lymphoplasmacytic infiltrate, storiform fibrosis or obliterative phlebitis are sufficient to confirm the histological diagnosis. Steroids are recommended as first-line therapy. Rituximab or disease-modifying antirheumatic drugs may be used in relapsed or rare cases of steroid-refractory disease. In this review, we summarize current knowledge regarding the pathophysiology, epidemiology, diagnostic modalities (clinical-biological-imaging-histopathology) and treatment of IgG4-RD thoracic involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.